A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma
A new model of intratumor and interpatient heterogeneity in response to drug combinations explains and predicts the results of clinical trials of curative-intent treatments for DLBCL. This model can be used to understand and inform optimal design of curative drug combinations and clinical trials. See related commentary by Goldstein et al., p. 153.
Authors
- Amy E. Pomeroy (ORCID: https://orcid.org/0000-0001-9217-3539)
- Adam C. Palmer (ORCID: https://orcid.org/0000-0001-5028-7028)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- Blood Cancer Discovery
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1158/2643-3230.bcd-24-0230
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Sanofi
- National Cancer Institute
- National Institute of General Medical Sciences